Umbilical cord blood: Biology and transplantation

Expert Review of Hematology

Volumn 2, Issue 2, 2009, Pages 197-208

  Doan, Phuong L ^a   Chao, Nelson J ^a,b  

^a DUKE UNIVERSITY   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cord blood; Ex vivo stem cell expansion; Hematopoietic stem cell; Regenerative medicine; Transplantation

Indexed keywords

BUSULFAN; CD34 ANTIGEN; CHEMOKINE RECEPTOR CXCR4 ANTAGONIST; CYCLOPHOSPHAMIDE; FLT3 LIGAND; FLUDARABINE; THYMOCYTE ANTIBODY; TRANSCRIPTION FACTOR FOXP3;

BLOOD BANK; BONE MARROW TRANSPLANTATION; CD4+ CD25+ T LYMPHOCYTE; CELL HOMING; CHILDHOOD CANCER; CHIMERA; CORD BLOOD STEM CELL TRANSPLANTATION; DISEASE FREE SURVIVAL; ENGRAFTMENT; EPSTEIN BARR VIRUS; GENE EXPRESSION; GRAFT VERSUS LEUKEMIA EFFECT; HEMATOLOGIC MALIGNANCY; HLA MATCHING; HUMAN; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; IMMUNOLOGICAL TOLERANCE; IMMUNOPHENOTYPING; MORTALITY; MYELOABLATIVE CONDITIONING; NATURAL KILLER CELL; NONMYELOABLATIVE STEM CELL TRANSPLANTATION; OVERALL SURVIVAL; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PRIORITY JOURNAL; REGENERATIVE MEDICINE; REVIEW; STEM CELL MOBILIZATION; T LYMPHOCYTE; UMBILICAL CORD BLOOD; WHOLE BODY RADIATION;

ADULT; CHILD; CORD BLOOD STEM CELL TRANSPLANTATION; FETAL BLOOD; HUMANS;

EID: 77953369520     PISSN: 17474086     EISSN: None     Source Type: Journal    
DOI: 10.1586/ehm.09.9     Document Type: Review

References (108)

1. Mayani H, Lansdorp PM. Biology of human umbilical cord blood-derived hematopoietic stem/progenitor cells. Stem Cells 16(3), 153-165 (1998).
2. Traycoff CM, Abboud MR, Laver J et al. Evaluation of the in vitro behavior of phenotypically defined populations of umbilical cord blood hematopoietic progenitor cells. Exp. Hematol. 22(2), 215-222 (1994).
3. Broxmeyer HE, Hangoc G, Cooper S et al. Growth characteristics and expansion of human umbilical cord blood and estimation of its potential for transplantation in adults. Proc. Natl Acad. Sci. USA 89(9), 4109-4113 (1992).
4. Hows JM, Bradley BA, Marsh JCW et al. Growth of human umbilical cord blood in long-term hematopoietic cultures. Lancet 340(8811), 73-76 (1992).
5. Mayani H, Gutierrez-Rodriguez M, Espinoza l et al. Kinetics of hematopoiesis in Dexter-type long-term cultures established from human umbilical cord blood cells. Stem Cells 16(2), 127-135 (1998).
6. McNiece IK, Stewart FM, Deacon DM et al. Detection of a human CFC with a high proliferative potential. Blood 74(2), 609-615 (1989).
7. Lu L, Xiao M, Shen R-N, Grisby S, Broxmeyer HE. Enrichment, characterization and responsiveness of single primitive CD34 human umbilical cord blood hematopoietic progenitors with high proliferative and replating potential. Blood 81(1), 41-48 (1993).
8. Vaziri H, Dragowska W, Allsopp RC, Thomas TE, Harley CB, Lansdrop PM. Evidence for a mitotic clock in human hematopoietic stem cells: loss of telomeric DNA with age. Proc. Natl Acad. Sci. USA 91(21), 9857-9860 (1994).
9. Pentengell R, Luft T, Henschler R et al. Direct comparison by limiting dilution analysis of long-term culture initiating cells in human bone marrow, umbilical cord blood and blood stem cells. Blood 84(11), 3652-3659 (1994).
10. Han P, Hodge G, Story C, Xu X. Phenotypic analysis of functional T-lymphocytes and natural killer cells in human cord blood: relevance to umbilical cord blood transplantation. Br. J. Haematol. 89(4), 733-740 (1995).
11. Szabolcs P, Park KD, Reese M, Marti L, Broadwater G, Kurtzberg J. Coexistent naïve phenotype and higher cycling rate of cord blood T cells as compared to adult peripheral blood. Exp. Hematol. 31(8), 708-714 (2003).
12. Chalmers IM, Jannossy, Contreras M, Navarrete C. Intracellular cytokine profile of cord and adult blood lymphocytes. Blood 92(1), 11-18 (1998).
13. Kollet O, Spiegel A, Peled A et al. Rapid and efficient homing of human CD34(+)CD38(/ low)CXCR4(+) stem and progenitor cells to the bone marrow and spleen of NOD/SCID and NOD/SCID/B2m(null) mice. Blood 97(10), 3283-3291 (2001).
14. Peled A, Kollet O, Ponomarylov T et al. The chemokine SDF-1 activates the integrins LFA-1, VLA-4, and VLA-5 on immature human CD34+ cells: role in the transendothelial/stromal migration and engraftment in NOD/SCID mice. Blood 95(11), 3289-3296 (2000).
15. Lapidot T, Dar A, Kollet O. How do stem cells find their way home? Blood 106(6), 1901-1910 (2005).
16. Peled A, Petit I, Kollet O et al. Dependence of human stem cell engraftment and repopulation of NOD/SCID mice in CXCR4. Science 283(5403), 845-848 (1999).
17. Petit I, Szyper-Kravitz M, Nagler A et al. G-CSF induces stem cell mobilization by decreasing bone marrow sdf-1 and upregulating CXCR4. Nat. Immunol. 3(7), 687-694 (2002).
18. Kahn J, Byk T, Jansson-Sjostrand L et al. Overexpression of CXCR4 on human CD34+ progenitors increases their proliferation, migration, and NOD/SCID repopulation. Blood 103(8), 2942-2949 (2004).
19. Glimm H, Tang P, Clark-Lewis I et al. Ex vivo treatment of proliferating human cord blood stem cells with stroma-derived factor-1 enhances their ability to engraft NOD/SCID mice. Blood 99(9), 3454-3457 (2002).
20. Roy V, Verfaillie CM. Expression and function of cell adhesion molecules on fetal liver, cord blood and bone marrow hematopoietic progenitors: implications for anatomic localization and developmental stage specific regulation of hematopoiesis. Exp. Hematol. 27(2), 302-312 (1999).
21. Ng YY, van Kessel B, Lokhorst HM et al. Gene-expression profiling of CD34+ cells from various hematopoietic stem-cell sources reveals functional differences in stem-cell activity. J. Leukoc. Biol. 75(2), 314-323 (2004).
22. Parkman R, Cohen G, Carter SL et al. Successful immune reconstitution decreases leukemic relapse and improves survival in recipients of unrelated cord blood transplantation. Biol. Blood Marrow Transplant. 12(9), 919-927 (2006).
23. Kamanduri KV, St John LS, de Lima M et al. Delayed immune reconstitution after cord blood transplantation is characterized by impaired thymopoiesis and late memory T-cell skewing. Blood 110(13), 4543-4551 (2007).
24. Parody R, Martino R, Rovina M et al. Severe infections after unrelated donor allogeneic hematopoietic stem cell transplantation in adults: comparison of cord blood transplantation with peripheral blood and bone marrow transplantation. Biol. Blood Marrow Transplant. 12(7), 734-748 (2006).
25. Brunstein CG, Weisdorf DJ, Defor T et al. Marked increased risk of Epstein-Barr virus-related complications with the addition of antithymocyte globulin to a nonmyeloablative conditioning prior to unrelated umbilical cord blood transplantation. Blood 108(8), 2874-2880 (2006).
26. Albano MS, Taylor P, Pass RF et al. Umbilical cord blood transplantation and cytomegalovirus: post-transplantation infection and donor screening. Blood 108(13), 4275-4282 (2006).
27. Civin CI, Strauss LC, Brovall C, Fackler MJ, Schwartz JF, Shaper JH. Antigenic analysis of hematopoiesis III. A hematopoietic progenitor cell surface antigen defined by a monoclonal antibody raised against KG-Ia cells. J. Immunol. 133(1), 157-165 (1984).
28. Healy L, May G, Gale K, Grosveld F, Greaves M, Enver T. The stem cell antigen CD34 functions as a regulator of hematopoietic cell adhesion. Proc. Natl Acad. Sci. USA 92(26) 12240-12244 (1995).
29. Kinniburgh D, Russell NH. Comparative study of CD34-positive cells and subpopulations in human umbilical cord blood and bone marrow. Bone Marrow Transplant. 12(5), 489-494 (1993).
30. Thilaganathan B, Nicolaides KH, Morgan G. Subpopulations of CD34-positive haematopoietic progenitors in fetal blood. Br. J. Haematol. 87(3), 634-636 (1994).
31. Craig W, Kay R, Cutler RL, Lansdrop PM. Expression of Thy-1 on human hematopoietic progenitor cells. J. Exp. Med. 177(5), 1331-1338 (1993).
32. Mayani H, Lansdrop PM. Thy-1 expression is linked to functional properties of primitive hematopoietic progenitor cells from human umbilical cord blood. Blood 83(9), 2410-2417 (1994).
33. Anderson DM, Lyman SD, Baird A et al. Molecular cloning of mast cell growth factor, a hemopoietin that is active in both membrane bound and soluble forms. Cell 63(1), 235-242 (1990).
34. Rappold I, Ziegler BL, Köhler I et al. Functional and phenotypic characterization of cord blood and bone marrow subsets expressing FLT3 (CD135) receptor kinase. Blood 90(1), 111-125 (1997).
35. Saeland S, Duvert V, Caux C et al. Distribution of surface-membrane molecules on bone marrow and cord blood CD34+ hematopoietic cells. Exp. Hematol. 20(1), 24-33 (1992).
36. Kimura T, Asada R, Wang J et al. Identification of long-term repopulating potential of human cord blood-derived CD34-flt3-severe combined immunodeficiency-repopulating cells by intrabone marrow injection. Stem Cells 25(6), 1348-1355 (2007).
37. López MC, Palmer BE, Lawrence DA. Phenotypic differences between cord blood and adult peripheral blood. Cytometry B Clin. Cytom. 76B(1), 37-46 (2008).
38. Wagner JE, Barker JN, Defor TE et al. Transplantation of unrelated donor umbilical cord blood in 102 patients with malignant and nonmalignant diseases: influence of CD34 cell dose and HLA disparity on treatment-related mortality and survival. Blood 100(5), 1611-1618 (2002).
39. Godfrey WR, Spoden DJ, GeYG et al. Cord blood CD4+CD25+-derived T regulatory cells lines express FoxP3 protein and manifest potent suppressor function. Blood 105(2), 750-758 (2005).
40. Li L, Godfrey WR, Porter SB et al. CD4+CD25+ regulatory T cell lines from human cord blood have functional and molecular properties of T cell anergy. Blood 106(9), 3068-3073(2005).
41. Zhao Y, Lin B, Darflinger R, Zhang Y, Holterman MJ, Skidgel RA. Human cord blood stem cell- modulated regulatory T lymphocytes reverse the autoimmune caused-type I diabetes in nonobese diabetic (NOD) mice. PLoS ONE 4(1), e4226 (2009).
42. Van Rood JJ, Oudshoorn M. Eleven million donors in bone marrow donors worldwide! Time for reassessment? Bone Marrow Transplant. 41(1), 1-9 (2008).
43. McCullough J, McKenna D, Kadidlo D, Schierman T, Wagner J. Issues in the quality of umbilical cord blood stem cells for transplantation. Transfusion 45(6), 832-841 (2005). (Pubitemid 40798773)
44. Ballen KK, Barker JN, Stewart SK, Greene MF, Lane TA. Collection and preservation of cord blood for personal use. Biol. Blood Marrow Transplant. 14(3), 356-363 (2008).
45. American Academy of Pediatrics WGOCBB. Cord blood banking for potential future transplantation: subject review. American Academy of Pediatrics. Work Group on Cord Blood Banking. Pediatrics 104(1 Pt 1), 116-118 (1999).
46. Committee on Obstetric Practice; committee on genetics. ACOG committee opinion number 399, February 2008: umbilical cord blood banking. Obstet. Gynecol. 111(2 Pt 1), 475-477 (2008).
47. Gluckman E, Rocha V, Arcese W et al. Factors associated with outcomes of unrelated cord blood transplant: guidelines for donor choice. Exp. Hematol. 32(4), 397-407 (2004).
48. Rubinstein P, Stevens CE. Placental blood for bone marrow replacement: the New York Blood Center's program and clinical results. Baillieres Best Pract. Res. Clin. Haematol. 13(4), 565-584 (2000).
49. Gluckman E, Rocha V, Boyer-Chammard A et al. Outcome of cord-blood transplantation from related and unrelated donors: Eurocord Transplant Group and the European Blood and Marrow Transplantation Group. N. Engl. J. Med. 337(6), 373-381 (1997).
50. Barker J, Scaradavou A, Stevens C, Rubinstein P. Analysis of 608 umbilical cord blood transplants: HLA-match is a critical determinant of transplant-related mortality in the post-engraftment period evening the absence of acute graft-versushost disease. Blood 106, (2005) (Abstract 303).
51. Gluckman E, Rocha V. Donor selection for unrelated cord blood transplants. Curr. Opin. Immunol. 18(5), 565-570 (2006).
52. Gluckman E, Broxmeyer HA, Auerbach AD et al. Hematopoietic reconstitution in a patient with Fanconi's anemia by means of umbilical-cord blood from an HLAidentical sibling. N. Engl. J. Med. 321(17), 1174-1178 (1989).
53. Kurtzberg J, Laughlin M, Graham ML et al. Placental blood as a source of hematopoietic stem cells for transplantation into unrelated recipients. N. Engl. J. Med. 335(3), 157-166 (1996).
54. Eapen M, Rubinstein P, Zhang M-J et al. Outcomes of transplantation of unrelated donor umbilical cord blood and bone marrow in children with acute leukemia: a comparison study. Lancet 369(9577), 1947-1954 (2007).
55. Locatelli F, Nöllke P, Zecca M et al. Hematopoietic stem cell transplantation (HSCT) in children with juvenile myelomonocytic leukemia (JMML): results of the EWOG-MDS/EBMT trial. Blood 105(1), 410-419 (2004).
56. Kurtzberg J, Prasad VK, Carter S et al. Results of the Cord Blood Transplantation Study (COBLT): clinical outcomes of unrelated donor umbilical cord blood transplantation in pediatric patients with hematologic malignancies. Blood 112(10), 4318-4327 (2008).
57. Escolar ML, Poe MD, Provenzale JM et al. Transplantation of umbilical cord blood in babies with infantile Krabbe's disease. N. Engl. J. Med. 352(20), 2069-2081 (2005).
58. Laughlin MJ, Eapen M, Rubinstein P et al. Outcomes after transplantation of cord blood or bone marrow from unrelated donors in adults with leukemia. N. Engl. J. Med. 351(22), 2265-2275 (2004).
59. Rocha V, Labopin M, Sanz G et al. Transplants of umbilical-cord blood or bone marrow from unrelated donors in adults with acute leukemia. N. Engl. J. Med. 351(22), 2276-2285 (2004).
60. Takahashi S, Iseki T, Ooi J et al. Singleinstitute comparative analysis of unrelated bone marrow transplantation and cord blood transplantation for adult patients with hematologic malignancies. Blood 104(12), 3813-3820 (2004).
61. Takahashi S, Ooi J, Tomonari A et al. Comparative single-institute analysis of cord blood transplantation from unrelated donors with bone marrow or peripheral blood stem-cell transplants from related donors in adult patients with hematologic malignancies after myeloablative conditioning regimen. Blood 109(3), 1322-1330 (2007).
62. Cornetta K, Laughlin M, Cater S et al. Umbilical cord blood transplantation in adults: results of the prospective cord blood transplantation (COBLT). Biol. Blood Marrow Transplant. 11(2), 149-160 (2005). (Pubitemid 40186212)
63. Kumar P, Defor TE, Brunstein C et al. Allogeneic hematopoietic stem cell transplantation in adult acute lymphocytic leukemia: impact of donor source on survival. Biol. Blood Marrow Transplant. 14(12), 1394-1400 (2008).
64. Rodrigues CA, Sanz G, Brunstein CG et al. Analysis of risk factors for outcomes after unrelated cord blood transplantation in adults with lymphoid malignancies: a study by the Eurocord-Netcord and Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J. Clin. Oncol. 27(2), 256-263 (2009).
65. Barker JN, Weisdorf DJ, Defor TE et al. Transplantation of 2 partially HLA-matched umbilical cord blood units to enhance engraftment in adults with hematologic malignancy. Blood 105(3), 1343-1347 (2005).
66. Macmillan ML, Weisdorf DJ, Brunstein CG et al. Acute graft-versus-host disease after unrelated donor umbilical cord blood transplantation: analysis of risk factors. Blood 113(11), 2410-2415 (2008).
67. Arora M, Nagaraj S, Wagner JE et al. Chronic graft-versus-host disease (cGVHD) following unrelated donor hematopoietic stem cell transplantation (HSCT): higher response rate in recipients of unrelated donor (URD umbilical cord blood (UCB). Biol. Blood Marrow Transplant. 13(10), 1145-1152 (2007).
68. Mazurier F, Doedens M, Gan OI, Dick JE. Rapid myeloerythroid repopulation after intrafemoral transplantation of NOD- SCID mice reveals a new class of human stem cells. Nat. Med. 9(7), 959-963 (2003).
69. Klimczak A, Unal S, Jankowska A, Coburn C, Siemionow M. Donor-origin cell engraftment after intraosseous or intravenous bone marrow transplantation in a rat model. Bone Marrow Transplant. 40(4), 373-380 (2007).
70. Frassoni F, Gualandi F, Podesta M et al. Direct intrabone transplant of unrelated cord-blood cells in acute leukaemia: a Phase I/II study. Lancet Oncol. 9(9), 831-839 (2008).
71. Rizzieri DA, Long, GD, Vredenburg JJ et al. Successful allogeneic engraftment of mismatched unrelated cord blood following a nonmyeloablative preparative regimen. Blood 98(12), 3486-3488 (2001).
72. Barker JN, Weisdorf DJ, Defor TE, Blazer BR, Miller JS, Wagner JE. Rapid and complete donor chimerism in adult recipients of unrelated donor umbilical cord blood transplantation after reducedintensity conditioning. Blood 102(5), 1915-1919 (2003).
73. Koh L-P, Chao NJ. Umbilical cord blood transplantation in adults using myeloablative and nonmyeloablative preparative regimens. Biol. Blood Marrow Transplant. 10(1), 1-22 (2004).
74. Brunstein CG, Barker JN, Weisdorf DJ et al. Umbilical cord blood transplantation after nonmyeloablative conditioning: impact on transplantation outcomes in 110 adults with hematologic disease. Blood 110(8), 3064-3070 (2007).
75. Majhail NS, Brunstein CG, Tomblyn M et al. Reduced-intensity allogeneic transplant in patients older than 55 years: unrelated umbilical cord blood is safe and effective for patients without a matched related donor. Biol. Blood Marrow Transplant. 14(3), 282-289 (2008).
76. Majhail NS, Weisdorf DJ, Wagner JE, Defor TE, Brunstein CG, Burns LJ. Comparable results of umbilical cord blood and HLA-matched sibling donor hematopoietic stem cell transplantation after reducedintensity preparative regimen for advanced Hodgkin lymphoma. Blood 107(9), 3804-3807 (2006).
77. Mimeault M, Hauke R, Batra SK. Stem cells: a revolution in therapeutics - recent advances in stem cell biology and their therapeutic applications in regenerative medicine and cancer therapies. Clin. Pharmacol. Ther. 82(3), 252-264 (2007).
78. Murohara T, Ikeda H, Duan J et al. Transplanted cord blood-derived endothelial precursor cells augment postnatal neovascularization. J. Clin. Invest. 105(11), 1527-1536 (2000).
79. Pomyje J, Zivny J, Sefc L, Plasilova M, Pytlik R, Necas E. Expression of genes regulating angiogenesis in human circulating hematopoietic cord blood CD34+/CD133+ cell. Eur. J. Haematol. 70(3), 143-150 (2003).
80. Ma N, Stamm C, Kaminski A et al. Human cord blood cells induce angiogenesis following myocardial infarction in NOD/SCID-mice. Cardiovasc. Res. 66(1), 45-54 (2005).
81. Hu CH, Wu GF, Wang XQ et al. Transplanted human umbilical cord blood mononuclear cells improve left ventricular function through angiogenesis in myocardial infarction. Chin. Med. J. (Engl.) 119(18), 1499-1506 (2006).
82. Kim BO, Tian H, Prasongsukarn K et al. Cell transplantation improves ventricular function after a myocardial infarction: a preclinical study of human unrestricted somatic stem cells in a porcine model. Circulation 112(9 Suppl.), I96-I104 (2005).
83. Bachsetter AD, Pabon MM, Col MJ et al. Peripheral injection of human umbilical cord blood stimulates neurogenesis in the aged rat brain. BMC Neurosci. 9(1), 22-30 (2008).
84. Lu D, Sanberg PR, Mahmood A et al. Intravenous administration of human umbilical cord blood reduces neurological deficit in the rat after traumatic brain injury. Cell Transplant. 11(3), 275-281 (2002).
85. Zhao ZM, Li HJ, Liu HY. Intraspinal transplantation of CD34+ human umbilical cord blood cells after spinal cord hemisection injury improves functional recovery in adult rats. Cell Transplant. 13(3), 113-122 (2004).
86. Chen N, Hudson JE, Walczak P et al. Human umbilical cord blood progenitors: the potential of these hematopoietic cells to become neural. Stem Cells 23, 156-170 (2005).
87. Zangiacomi V, Balon N, Maddens S et al. Cord blood-derived neurons are originated from CD133+/CD34 stem/progenitor cells in a cell-to-cell contact dependent manner. Stem Cells Dev. 17(5), 1005-1016 (2008).
88. Piacibello W, Sanavio F, Garetto L et al. Extensive amplification and self-renewal of human primitive hematopoietic stem cells from cord blood. Blood 89(8), 2644-2653 (1997).
89. Lim CK, Sun L, Feng Q. Effect of anti-52 antibody alemtuzumab on ex-vivo culture of umbilical cord blood stem cells. J. Hematol. Oncol. 1, 19-29 (2008).
90. De Felice L, Tatarelli C, Mascolo MG et al. Histone deacetylase inhibitor valproic acid enhances the cytokine-induced expansion of human hematopoietic stem cells. Cancer Res. 65(4), 1505-1513 (2005).
91. Karanu FN, Murdoch B, Gallacher L et al. The Notch ligand Jagged-1 represents a novel growth factor of human hematopoietic stem cells. J. Exp. Med. 192(9), 1365-1372 (2000).
92. Reya T, Duncan AW, Ailles L et al. A role for Wnt signaling in self-renewal of haematopoietic stem cells. Nature 423(6938), 409-414 (2003).
93. Bakshi T, Zabriske RC, Bodie S et al. Mesenchymal stem cells from the Wharton's jelly of umbilical cord segments provide stromal support for the maintenance of cord blood hematopoietic stem cells during long-term ex vivo culture. Transfusion 48(12), 2638-2644 (2008).
94. Chan SL, Choi M, Wnendt S et al. Enhanced in vivo homing of uncultured and selectively amplified cord blood CD34+ cells by cotransplantation with cord bloodderived unrestricted somatic stem cells. Stem Cells 25(2), 529-536 (2007).
95. Robinson SN, Ng J, Niu T et al. Superior ex vivo cord blood expansion following co-culture with bone marrow-derived mesenchymal stem cells. Bone Marrow Transplant. 37(4), 359-366 (2006).
96. Shpall EJ, Quinones R, Giller R et al. Transplantation of ex vivo expanded cord blood. Biol. Blood Marrow Transplant. 8(7), 368-376 (2002).
97. Wagner JE, Rosenthal J, Sweetman R et al. Successful transplantation of HLA-matched and HLA-mismatched umbilical cord blood from unrelated donors: analysis of engraftment and acute graft-versus-host disease. Blood 88(3), 795-802 (1996).
98. Jaroscak J, Goltry K, Smith A et al. Augmentation of umbilical cord blood (UCB) transplantation with ex vivoexpanded UCB cells: results of a Phase I trial using the Aastrom Replicell System. Blood 101(12), 5061-5067 (2003).
99. Peled T, Landau E, Prus E, Treves A, Nagler A, Fibach E. Cellular copper content modulates differentiation and self-renewal in cultures of cord blood-derived CD34+ cells. Br. J. Haematol. 116(3), 655-661(2002).
100. Peled T, Gluckman E, Hasson N et al. Chelatable cellular copper modulates differentiation and self-renewal of cordblood derived hematopoietic progenitor cells. Exp. Hematol. 33(10), 1092-1100 (2005).
101. De Lima M, McMannis J, Gee A et al. Transplantation of ex vivo expanded cord blood cells using the copper chelator tetraethylenepentamine: a Phase I/II clinical trial. Bone Marrow Transplant. 41(9), 771-778 (2008).
102. Glimm H, Schmidt M, Fischer M et al. Efficient marking of human cells with rapid but transient repopulating activity in autografted recipients. Blood 106(3), 893-898 (2005).
103. Chute JP, Muramoto GG, Salter AB et al. Transplantation of vascular endothelial cells mediates the hematopoietic recovery of lethally irradiated mice. Blood 109(6), 2365-2372 (2007).
104. Salter AB, Meadows SK, Muramoto GG et al. Endothelial progenitor cell infusion induces hematopoietic stem cell reconstitution in vivo. Blood 113(9), 2104-2107 (2009).
105. MacMillian ML, Blazer BR, Defor TE, Wagner JE. Transplantation of ex vivo culture-expanded parental haploidentical mesenchymal stem cells to promote engraftment in pediatric recipients of unrelated donor umbilical cord blood: results of a Phase I-II clinical trial. Bone Marrow Transplant. (2008) (Epub ahead of print).
106. Ende M, Ende N. Hematopoietic transplantation by means of fetal (cord) blood. Va Med. Mon. 99(3), 276-280 (1972).
107. Margo E, Regidor C, Cabera R et al. Early hematopoietic recovery after single unit unrelated cord blood transplantation in adults supported by co-infusion of mobilized stem cells from a third party donor. Haematologica 91(5), 640-648 (2006).
108. Dainiak N, Ricks RC. The evolving role of haematopoietic cell transplantation in radiation injury: potentials and limitations. BJR Suppl. 27, 169-174 (2005).